Product Description
Dirocaftor is a type of CFTR modulator called a potentiator.
Mechanisms of Action: CTFR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yumanity Therapeutics
Company Location: BOSTON MA 02135
Company CEO: Richard Peters
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HIT-CF-001 | P2 |
Unknown Status |
Cystic Fibrosis |
2025-06-30 |
|
HIT-CF-001 | P3 |
Unknown Status |
Cystic Fibrosis |
2024-09-30 |
|
PTI-808-01 | P2 |
Completed |
Cystic Fibrosis |
2019-12-23 |
|
2017-003319-21 | P2 |
Completed |
Cystic Fibrosis |
2019-12-23 |